Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 743

Showing 26-50 of 743 citing articles:

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Julio Rosenstock, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10401, pp. 529-544
Closed Access | Times Cited: 210
Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial
Barham K. Abu Dayyeh, Fateh Bazerbachi, Eric J. Vargas, et al.
The Lancet (2022) Vol. 400, Iss. 10350, pp. 441-451
Closed Access | Times Cited: 209
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail Kosiborod, Mark C. Petrie, Barry A. Borlaug, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 15, pp. 1394-1407
Closed Access | Times Cited: 187
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Takashi Kadowaki, Joakim Isendahl, Usman Khalid, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 3, pp. 193-206
Closed Access | Times Cited: 183
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S128-S139
Open Access | Times Cited: 177
8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes:Standards of Medical Care in Diabetes—2022

Diabetes Care (2021) Vol. 45, Iss. Supplement_1, pp. S113-S124
Open Access | Times Cited: 173
Clinical management and treatment of obesity in China
Qiang Zeng, Naishi Li, Xiong‐Fei Pan, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 6, pp. 393-405
Closed Access | Times Cited: 170
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
Francisco López-Jiménez, Wael Almahmeed, Harold Bays, et al.
European Journal of Preventive Cardiology (2022) Vol. 29, Iss. 17, pp. 2218-2237
Open Access | Times Cited: 168
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
Tim Heise, Andrea Mari, J. Hans DeVries, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 6, pp. 418-429
Closed Access | Times Cited: 164
Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants
Nicholas Syn, David E. Cummings, Louis Z Wang, et al.
The Lancet (2021) Vol. 397, Iss. 10287, pp. 1830-1841
Closed Access | Times Cited: 162
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S77-S110
Open Access | Times Cited: 142
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 720-730
Closed Access | Times Cited: 135
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans
Journal of Investigative Medicine (2021) Vol. 70, Iss. 1, pp. 5-13
Open Access | Times Cited: 129
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
Mojca Jensterle, Manfredi Rizzo, Martin Haluzı́k, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2452-2467
Open Access | Times Cited: 128
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Wissam Ghusn, Alan De la Rosa, Daniel Sacoto, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2231982-e2231982
Open Access | Times Cited: 128
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Eduardo Grunvald, Raj Shah, Rubén Hernáez, et al.
Gastroenterology (2022) Vol. 163, Iss. 5, pp. 1198-1225
Open Access | Times Cited: 126
Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
Liyun He, Jialu Wang, Fan Ping, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 5, pp. 513-513
Open Access | Times Cited: 125
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Javed Butler, Sanjiv J. Shah, Mark C. Petrie, et al.
The Lancet (2024) Vol. 403, Iss. 10437, pp. 1635-1648
Open Access | Times Cited: 125
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 124
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Jingyue Wang, Quanwei Wang, Xinyu Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 120
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 29-38
Open Access | Times Cited: 118
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
Sean Wharton, Melanie J. Davies, Dror Dicker, et al.
Postgraduate Medicine (2021) Vol. 134, Iss. 1, pp. 14-19
Open Access | Times Cited: 108
Semaglutide for the treatment of overweight and obesity: A review
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 18-35
Open Access | Times Cited: 106
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 103
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 103

Scroll to top